These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sensitivity of Hodgkin's lymphoma cell lines to the cell cycle inhibitor roscovitine. Foell JL; Max D; Giersberg C; Korholz D; Staege MS Anticancer Res; 2008; 28(2A):887-94. PubMed ID: 18507033 [TBL] [Abstract][Full Text] [Related]
6. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. Kewitz S; Staege MS PLoS One; 2013; 8(2):e55897. PubMed ID: 23409080 [TBL] [Abstract][Full Text] [Related]
7. Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells. Kewitz S; Staege MS Front Oncol; 2013; 3():179. PubMed ID: 23847767 [TBL] [Abstract][Full Text] [Related]
8. The hypoxia-mimetic agent CoCl₂ induces chemotherapy resistance in LOVO colorectal cancer cells. Yang G; Xu S; Peng L; Li H; Zhao Y; Hu Y Mol Med Rep; 2016 Mar; 13(3):2583-9. PubMed ID: 26846577 [TBL] [Abstract][Full Text] [Related]
9. Melittin Increases Cisplatin Sensitivity and Kills KM-H2 and L-428 Hodgkin Lymphoma Cells. Kreinest T; Volkmer I; Staege MS Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396195 [TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342 [TBL] [Abstract][Full Text] [Related]
11. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes]. Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984 [TBL] [Abstract][Full Text] [Related]
12. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065 [TBL] [Abstract][Full Text] [Related]
13. Identification of crucial genes and prediction of small molecules for multidrug resistance of Hodgkin's lymphomas. Huang Y; Huang Y; Zhang L; Chang A; Zhao P; Chai X; Wang J Cancer Biomark; 2018; 23(4):495-503. PubMed ID: 30347596 [TBL] [Abstract][Full Text] [Related]
15. Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. Carbone A; Gloghini A; Castagna L; Santoro A; Carlo-Stella C J Pathol; 2015 Sep; 237(1):4-13. PubMed ID: 25953622 [TBL] [Abstract][Full Text] [Related]
16. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892 [TBL] [Abstract][Full Text] [Related]
17. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia]. Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154 [TBL] [Abstract][Full Text] [Related]
20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A; J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]